Cyrus M. Khan, MD, discusses how treatment paradigms for chronic lymphocytic leukemia have changed in recent years, particularly regarding frontline therapy options.
Cyrus M. Khan, MD
Dr. Khan is a hematologist with the AHN Cancer Institute. He specializes in treating disorders and cancers of the blood, such as lymphoma, leukemia, myeloma (hematological malignancies). He is skilled in treatments for these conditions, including stem cell transplantation, cellular therapy, and CAR T-cell therapy.
Dr. Khan is involved in hematology research and has published in medical journals and presented his findings at national conferences. He supports AHN’s community outreach through the Leukemia & Lymphoma Society. He speaks English, Urdu, Pushto, and Persian.
He earned his medical degree from Ayub Medical College in Abbottabad, Pakistan. He completed his residency at Baystate Medical Center in Springfield, MA. He continued his studies through a hematology fellowship at the AGH-WPH Medical Education Consortium in Pittsburgh, PA.
Articles by Cyrus M. Khan, MD
Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.
Cyrus M. Khan, MD, discusses the eligibility criteria of a phase 1/2 study evaluating glofitamab for the treatment of patients with large B-cell lymphoma, and provides data from the expansion cohorts of the trial.
Cyrus M. Khan, MD, discusses pirtobrutinib for the treatment of mantle cell lymphoma and findings from the phase 1/2 BRUIN study.
Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.
Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.
Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.
In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.
Cyrus M. Khan, MD, discusses the most recent findings that show the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Cyrus M. Khan, MD, discusses the mechanism of action of glofitamab and its potential use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.
Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.
Latest Updated Articles
Evaluating Glofitamab as a Potential Option for Patients With R/R LBCLPublished: January 24th 2023 | Updated:
- Glofitamab Leads to Responses in Relapsed/Refractory LBCL
Published: October 14th 2023 | Updated:
Revolutionizing CLL Care With Targeted and Cellular TherapiesPublished: October 19th 2024 | Updated:
- CLL Treatment Advances and Frontline Therapy Insights With Dr. Khan
Published: February 7th 2025 | Updated: